Links for fulltext
     (May Require Subscription)

Conference Paper: Efficacy of post liver transplant hepatitis B booster vaccination in chronic hepatitis B recipients with prior immune response

TitleEfficacy of post liver transplant hepatitis B booster vaccination in chronic hepatitis B recipients with prior immune response
Authors
Issue Date2014
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021
Citation
The 2014 Joint International Congress of ILTS, ELITA and LICAGE, London, UK., 4-7 June 2014. In Liver Transplantation, 2014, v. 20 suppl. S1, p. S350, abstract no. P-646 How to Cite?
AbstractBACKGROUND: Previous study has shown that the presence of anti-HBs in HBV recipients after LT in the absence of HBIG and use of Pre-S containing HBV vaccine (Sci-B-VacTM), induced immune response in half of the patients. This study aims to determine the efficacy of booster vaccine in selected patients after LT. METHOD: Patients who had LT for HBV with either; group 1) previous immune response from vaccination; 2) detected anti-HBs for >1 year after LT or 3) peak anti-HBs >100 IU/ml. All received intramuscular injection of double dose Sci-B-VacTM. The primary end point was production of anti-HBs>10 IU/L (from previous negative value) or 2-fold increase from baseline was considered positive response. HBV serologies & HBV specific immune responses were taken at baseline, day 14, month 1,2,3,4,5 & 6 afterwards. RESULTS: 86 patients were recruited and 21 (24.4%) had responded. All five patients in group 1 responded, 7/45 (15.6%) in group 2 and 9/36 (25%) in group 3 responded (p<0.001). .Serial changes in anti-HBs in responders was shown in Figure 1. Responder and non-responder were the same in terms of age, sex, blood group, type of LT and indication. Production of anti-HBs was also independent of e antigen status and HBV DNA level before LT but non-responders were more likely to have HBV mutant(21.5 vs. 0%, p=0.04).Responders had significantly higher peak anti-HBs before booster (193 vs. 29 IU/ ml, p=0.011) and were less likely to have anti-HBs loss (57.1 vs. 81.5%, p=0.024).Univariate analysis showed that anti-HBs loss and peak anti-HBs before booster vaccination, age of recipients and HBV immune donors were significant predictors while peak anti-HBs level before booster vaccination was the only significant predictors on multivariate analysis. CONCLUSION: HBV vaccine has limited efficacy in patients after LT. Further studies are needed to identify who would benefit most from active immunization and to increase response rate.
DescriptionPoster Session 3 - Outcomes: P-646
This free journal suppl. entitled: The ILTS 20th Annual International Congress
Persistent Identifierhttp://hdl.handle.net/10722/201287
ISSN
2015 Impact Factor: 3.951
2015 SCImago Journal Rankings: 1.763

 

DC FieldValueLanguage
dc.contributor.authorWong, CLT-
dc.contributor.authorFung, JYY-
dc.contributor.authorChok, KSH-
dc.contributor.authorCheung, TT-
dc.contributor.authorChan, ACY-
dc.contributor.authorDai, JWC-
dc.contributor.authorSharr, W-
dc.contributor.authorTsang, SHY-
dc.contributor.authorCheung, CKY-
dc.contributor.authorChan, SC-
dc.contributor.authorLo, CM-
dc.date.accessioned2014-08-21T07:20:20Z-
dc.date.available2014-08-21T07:20:20Z-
dc.date.issued2014-
dc.identifier.citationThe 2014 Joint International Congress of ILTS, ELITA and LICAGE, London, UK., 4-7 June 2014. In Liver Transplantation, 2014, v. 20 suppl. S1, p. S350, abstract no. P-646-
dc.identifier.issn1527-6465-
dc.identifier.urihttp://hdl.handle.net/10722/201287-
dc.descriptionPoster Session 3 - Outcomes: P-646-
dc.descriptionThis free journal suppl. entitled: The ILTS 20th Annual International Congress-
dc.description.abstractBACKGROUND: Previous study has shown that the presence of anti-HBs in HBV recipients after LT in the absence of HBIG and use of Pre-S containing HBV vaccine (Sci-B-VacTM), induced immune response in half of the patients. This study aims to determine the efficacy of booster vaccine in selected patients after LT. METHOD: Patients who had LT for HBV with either; group 1) previous immune response from vaccination; 2) detected anti-HBs for >1 year after LT or 3) peak anti-HBs >100 IU/ml. All received intramuscular injection of double dose Sci-B-VacTM. The primary end point was production of anti-HBs>10 IU/L (from previous negative value) or 2-fold increase from baseline was considered positive response. HBV serologies & HBV specific immune responses were taken at baseline, day 14, month 1,2,3,4,5 & 6 afterwards. RESULTS: 86 patients were recruited and 21 (24.4%) had responded. All five patients in group 1 responded, 7/45 (15.6%) in group 2 and 9/36 (25%) in group 3 responded (p<0.001). .Serial changes in anti-HBs in responders was shown in Figure 1. Responder and non-responder were the same in terms of age, sex, blood group, type of LT and indication. Production of anti-HBs was also independent of e antigen status and HBV DNA level before LT but non-responders were more likely to have HBV mutant(21.5 vs. 0%, p=0.04).Responders had significantly higher peak anti-HBs before booster (193 vs. 29 IU/ ml, p=0.011) and were less likely to have anti-HBs loss (57.1 vs. 81.5%, p=0.024).Univariate analysis showed that anti-HBs loss and peak anti-HBs before booster vaccination, age of recipients and HBV immune donors were significant predictors while peak anti-HBs level before booster vaccination was the only significant predictors on multivariate analysis. CONCLUSION: HBV vaccine has limited efficacy in patients after LT. Further studies are needed to identify who would benefit most from active immunization and to increase response rate.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021-
dc.relation.ispartofLiver Transplantation-
dc.rightsLiver Transplantation. Copyright © John Wiley & Sons, Inc.-
dc.titleEfficacy of post liver transplant hepatitis B booster vaccination in chronic hepatitis B recipients with prior immune response-
dc.typeConference_Paper-
dc.identifier.emailWong, CLT: wongtcl@hku.hk-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailChok, KSH: chok6275@hku.hk-
dc.identifier.emailCheung, TT: cheung68@hku.hk-
dc.identifier.emailChan, ACY: acchan@hku.hk-
dc.identifier.emailDai, JWC: daiwc@hku.hk-
dc.identifier.emailSharr, W: wwsharr@hku.hk-
dc.identifier.emailCheung, CKY: cindycky@hku.hk-
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hk-
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.authorityWong, CLT=rp01679-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authorityChok, KSH=rp02110-
dc.identifier.authorityCheung, TT=rp02129-
dc.identifier.authorityChan, ACY=rp00310-
dc.identifier.authorityChan, SC=rp01568-
dc.identifier.authorityLo, CM=rp00412-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/lt.23901-
dc.identifier.hkuros234461-
dc.identifier.volume20-
dc.identifier.issuesuppl. S1-
dc.identifier.spageS350, abstract no. P-646-
dc.identifier.epageS350, abstract no. P-646-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats